Hem › Icke-småcellig lungcancer › Pennsylvania › Lancaster
Kliniska studier för Icke-småcellig lungcancer i Lancaster, PA
7 studier för Icke-småcellig lungcancer söker deltagare vid platser i och runt Lancaster (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
RekryterarFas 3
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0134), Lancaster
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
RekryterarFas 3
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0111), Lancaster
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
RekryterarFas 3
- Lancaster General Hospital, Lancaster
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
RekryterarFas 3
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0068), Lancaster
Pan-tumor MRD Study
RekryterarObservationsstudie
- Lancaster General Hospital (UPenn), Lancaster
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
RekryterarFas 3
- Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
RekryterarFas 3
- Research Site, Lancaster
Icke-småcellig lungcancer-studier i andra städer
- Houston, TX145 studier
- New York City, NY121 studier
- Arlington, VA104 studier
- Nashville, TN97 studier
- Boston, MA90 studier
- Los Angeles, CA87 studier
- St. Louis, MO73 studier
- Chicago, IL61 studier
- Baltimore, MD60 studier
- San Antonio, TX59 studier
- Columbus, OH57 studier
- Washington, DC55 studier
Andra studier i Lancaster
- Hjärt-kärlsjukdom5 studier
- Hjärtsvikt5 studier
- Bröstcancer4 studier
- Prostatacancer4 studier
- Metastaserande cancer4 studier
- Lungcancer3 studier
- Amblyopi3 studier
- Hjältsjukdomar3 studier
- Blåscancer3 studier
- Icke-muskelinvasiv blåscancer3 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.